

**VerifyNow**<sup>®</sup>  
System

## Antiplatelet Therapy Response Assessment

Verify now, because tomorrow is too late.



Rapid, easy, proven assessment.

**Accriva**  
diagnostics

## Antiplatelet therapy. *Is it working?*

Did you know that at least 1 in 3 patients on antiplatelet therapies are not receiving the intended physiological effect?<sup>1,2,3</sup> Can you make the right treatment decisions before understanding your patient's unique response to antiplatelet medications? Consider these facts:

- 40% of clopidogrel (Plavix®) users may not adequately respond to antiplatelet agents<sup>4</sup>
- Hyper-response is associated with an increased risk of bleeding
- Individual response to antiplatelet therapies can change over time
- Helps to identify non-compliance, which is often discovered too late

VerifyNow, the most cited and utilized FDA-cleared platelet reactivity test, may help identify patients at risk of a major adverse cardiac event (MACE) due to poor drug response. VerifyNow will tell you whether or not the antiplatelet medication you prescribed is safe and effective for your patient. It is an important tool among leaders throughout the healthcare system, serving areas in:

- Cardiology
- Surgery
- Anesthesiology
- Neurology
- Interventional neuroradiology
- Interventional radiology
- Trauma
- Emergency Department
- Blood utilization
- Pharmacy
- Physician Office Lab

### **VerifyNow testing supports better patient management.**

Make VerifyNow your new platelet function test system. Testing may:


- Identify PCI patients at risk for MACE
- Measure the effect of antiplatelet therapies prior to discharge
- Optimize patient length of stay prior to surgery
- Help reduce 30 day readmissions



## Aspirin Test

Whether used alone or as part of a dual anti-platelet therapy, aspirin is used by millions of patients suffering from one or more types of cardiovascular disease. As with other drug therapies, not all patients respond to aspirin equally.

Published studies indicate that up to 30% of patients show less than the expected level of platelet inhibition while on aspirin therapy, putting them at greater risk of heart attack, stroke, and other vascular events.<sup>1,2,3</sup>




**The VerifyNow Aspirin test aids in assessing how aspirin is affecting the patient's platelets and allows rapid, informed treatment decisions.**

## PRU Test

Some of the most commonly prescribed antiplatelet medications, including Plavix® (clopidogrel), Effient® (prasugrel) and Brilinta® (ticagrelor) are designed to specifically block the platelet P2Y12 receptor to reduce the risk of ischemic events.

However, patients with inadequate response to their antiplatelet medications may be at significantly greater risk of myocardial infarction, stent thrombosis, and death.



**The VerifyNow PRU Test measures the level of platelet P2Y12 receptor blockade to help identify patients who don't respond to antiplatelet medications.**

# The VerifyNow system uses a fully contained, single-use test device, providing sample-to-answer results.

VerifyNow is an indispensable aid to understanding the complete patient profile. Whether you're a cardiologist or surgeon, monitoring your patient's response to antiplatelet medication can optimize outcomes while ensuring the lowest financial burden for your patient.


## Clinically relevant results for less

- System reports platelet reactivity results in minutes
- Low-cost aspirin and P2Y12 Reaction Unit (PRU) tests
- Ensure patient drug response with the least expensive medication
- May help reduce 30-day hospital readmissions
- Effective therapy can improve patient outcomes

## Light Transmission Aggregometry (LTA)



VerifyNow uses a patented, LTA-correlated technology that is safe, accurate and intuitive. This test is pharma's gold standard technology for drug development and requires no sample manipulation, which eliminates analytical sample variation.

- Results within minutes
- No pipetting or sample preparation
- Easy integration into any lab workflow



## Contributing Factors

- Measures the degree of P2Y12 platelet receptor blockade, to aid in assessing patient response to antiplatelet therapy including clopidogrel (Plavix®), prasugrel (Effient®) and ticagrelor (Brilinta®).
- Measures the platelet response to aspirin by an arachidonic acid initiated reaction.
- Measures the patient response to IIb/IIIa inhibitors such as eptifibatid (Integrilin®) and abciximab (ReoPro®).



DECREASE IN DRUG EFFECT OVER TIME<sup>7</sup>

## How it Works

Factors contributing to variations in response to antiplatelet medication include **concomitant medications, genetic differences, current health conditions, and patient non-compliance.**

VerifyNow measures the platelet inhibitory response level in the patient through a state-of-the-art platelet function (PRUtest) and Aspirin Test. This allows for cardiologists and surgeons alike to make better, more individualized care decisions.

# How healthcare leaders are using VerifyNow.

*"Testing with VerifyNow supports ongoing expansion of the frontiers of endovascular aneurysm treatment by helping minimize risk of perioperative complications."*  
—**Josser E. Delgado, MD**  
(Neurointerventionalist)

*"I test all patients on platelet inhibitors prior to open heart surgery to assess whether or not antiplatelet therapies are having their desired effect."* —**Pierre R. Tibi, MD** (Cardiovascular Surgeon)

*"Having the VerifyNow system allows me to assess the effect of the chosen antiplatelet treatment strategies and make informed decisions."*  
—**Dr. J. Brent Muhlestein, MD**  
(Interventional Cardiologist)

## Ordering Information

Catalog Number	Description
85066	VerifyNow Instrument System (International)
86000	VerifyNow Instrument System
85053	VerifyNow Aspirin Test, 25-Test Kit
85225	VerifyNow PRU Test, 25-Test Kit

To learn more, visit [www.accriva.com](http://www.accriva.com)  
US Customers: 800.643.1640  
International Customers: 858.263.2501

1 Gurbel, P. et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol. 2007;50(19):1822-34. 2 Krasopoulos, W. et al. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008;336(7637):195-8. 3 Steinhubl, S. et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event following percutaneous coronary intervention Results of the GOLD (AU - Assessing Ultegra) multicenter study. Circulation 2001;103(21):1403-1409. 4 ADAPT DES. The Lancet, Volume 382, Issue 9892, Pages 614 - 623, August 17, 2013. 5 VerifyNow Aspirin Test [package insert]. San Diego, CA; Accumetrics®; Revised April 2011. 6 VerifyNow PRU Test [package insert]. San Diego, CA; Accumetrics®; Revised April 2011. 7 Price, MJ et al, J Am Coll Cardiol 2012;59:2338-43.



Accriva Diagnostics, Inc. | 6260 Sequence Drive | San Diego, CA 92121 USA  
Tel: 858.263.2300 | Toll-Free: 800.631.5945 | [www.accriva.com](http://www.accriva.com)